Trevena Inc. (TRVN) presented positive Phase 2b results Monday August 31 from its TRV130 pain study. The primary endpoint of superior pain reduction compared to placebo was met, as well as.
Bio Blast Pharma Ltd. (ORPN) – Nasdaq BioBlast Pharma (ORPN) is a clinical-stage biotech company, focused on treatments for rare and ultra-rare diseases, especially genetic and metabolic diseases. The company has three.
Trillium Therapeutics Inc. (TRIL) – Nasdaq Trillium (TRIL) is developing the next-generation of cancer immunotherapies. TRIL’s lead program, SIRPαFc, targets CD47 to prevent cancer cells from delivering a “do not eat”.
Mannkind, the maker of the inhaled insulin product Afrezza, is the 11th best performing biotech stock according to Finviz in the last month, up 62%. That performance is in line.
13F filings have arrived and it’s like Christmas day for me. I’ve been pouring through the filings, tweeting the interesting ones, and probably annoying everyone on twitter. These filings are.
At the end of each month Chimera Research Group provides you with a monthly summary of ten notable catalysts/events that have been completed during the past month. APRIL 2015: Gilead.
Cynapsus is developing a sublingual film formulation of apomorphine for the treatment of acute “Off” episodes in patients with Parkinson’s Disease resulting from long term use of Levodopa. While Levodopa.
At the end of each month Chimera Research Group provides you with a monthly summary of TEN notable catalysts/events that have occurred during the past month. MARCH 2015: 1) Bristol-Myers Squibb Company (NYSE:BMY).
Bristol-Myers Squibb Company (BMY) –NYSE Bristol-Myers Squibb Co. (BMY) had a wild year, up from the lows of $47.54 in mid October 2014 to reach a new 12 years high.
Adamas Pharmaceuticals, Inc. (ADMS) –Nasdaq Adamas (ADMS) is a company focused on CNS diseases, specifically Parkinson’s (PD) and Alzheimer’s Diseases (AD). It has a low market cap (~$300M), plenty of.
Adamas Pharmaceuticals, Inc. (ADMS) –Nasdaq Adamas pharmaceutical had its initial public offering last year April 10th, the closing of its IPO of 3 million shares at a public offering.
Marinus Pharmaceuticals is developing the allopregnanolone analog Ganaxolone as a treatment for epilepsy and other seizure disorders. Its most advanced program is a multinational P3 trial of patients with refractory.
At the end of each month Chimera Research Group provides you with a monthly summary of notable catalysts that have been completed during the past month. February 2015: GILD provided.
San Diego’s Pfenex Inc. is riding the market’s enthusiasm for biosimilars, molecules that although not considered identical, can be automatically substituted for biologic drugs. Previously considered immune to generic competition,.
iShares Nasdaq Biotechnology (IBB) – Nasdaq As tweeted several time last and early this week, signs of weakness in the IBB Signs of weakness in the $IBB ..Start forming a Bearish.
At the end of each month Chimera Research Group provides you with a monthly summary of notable catalysts that have been completed during the past month. JANUARY 2015: 1) Bristol-Myers.
A quick update on CBSTZ the Cubist CVR. Today Cubist filed an 8-K notifying CVR holders that it intends to purchase all the CVRs at $0.059225 on February 2, 2015..
At the end of each month Chimera Research Group provides you with a monthly summary of notable catalysts that have been completed during the past month. DECEMBER 2014: 1) AbbVie.
This week started with a merger Monday. Cubist Pharmaceuticals agreed to be acquired by Merck & Company for $9.5B including assumption of debt. CBST traded like one would expect on.
Bristol-Myers Squibb Company (BMY) -NYSE Interesting price action since October 15th, after touching the support line $47.52 and bouncing back to start a new uptrend, we were looking to reach.
GWPH has been on one huge rollercoaster. After climbing back from $61 in mid-October to $80 in late November, it has given up 15% in just the last 3 trading.
The year is nearly over, though it feels like scientific conferences never end. December 6th marks the last big Cancer meeting of the year- then we turn the page to.
Earlier today on twitter there was a robust debate about the weakness seen in GILD and how this is related to fears on the upcoming competition from ABBV/ENTA. It seemed.
GW Pharma’s Tuesday morning R&D meeting looked pretty good. Efficacy data were released for 58 patients with full 12-weeks of epidiolex treatment- 40 of whom have been treated for 16-weeks..
The only new data provided by Sarepta were various measures of lung function, including, including %predicted MIP, MEP, and FVC; all of which demonstrated stabilization through 144 weeks for the.
Conatus Pharmaceuticals Inc. (CNAT) –Nasdaq CNAT was trading within a downtrend channel since June 16th after reaching the high of $9.90, finding a base around the $6.00 weekly support line.